- Home
- GOOD vs ADCT Comparison
GOOD vs ADCT Comparison
Compare GOOD & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOOD | ADCT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.4M | 483.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GOOD | ADCT |
|---|---|---|
| Price | $10.65 | $3.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $11.00 | $7.60 |
| AVG Volume (30 Days) | 537.8K | ★ 2.0M |
| Earning Date | 11-03-2025 | 11-10-2025 |
| Dividend Yield | ★ 11.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $155,250,000.00 | $75,209,000.00 |
| Revenue This Year | $8.62 | $10.36 |
| Revenue Next Year | $6.07 | $3.87 |
| P/E Ratio | $58.97 | ★ N/A |
| Revenue Growth | 4.95 | ★ 6.35 |
| 52 Week Low | $10.47 | $1.05 |
| 52 Week High | $16.63 | $4.80 |
Technical Indicators
Market Signals| Indicator | GOOD | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 44.74 |
| Support Level | $10.80 | $3.56 |
| Resistance Level | $11.13 | $4.05 |
| Average True Range (ATR) | 0.17 | 0.42 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 5.83 | 47.20 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).